FDA grants accelerated approval to ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL March 26, 2024
FDA Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for FRα-positive, platinum-resistant ovarian cancer (PROC) March 26, 2024
NMPA grants Approval to Tunlametinib (HL-085) for Patients with NRAS Mutated Advanced Melanoma and Previously Treated with PD-1/PD-L1 March 26, 2024
Abecma (idecabtagene vicleucel) Approved in the European Union in Earlier Lines for Triple-Class Exposed R/R Multiple Myeloma March 26, 2024
FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy March 19, 2024
U.S. FDA Approves Opdivo + Cisplatin + Gemcitabine for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma March 12, 2024
RYBREVANT® (amivantamab-vmjw) + Chemo gets FDA approval for First-line Treatment of Patients With NSCLC with EGFR Exon 20 Insertion Mutations March 12, 2024
TECVAYLI® (teclistamab-cqyv) biweekly dosing approved by the U.S. FDA for the treatment of patients with R/R multiple myeloma February 26, 2024
Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer February 26, 2024
Onivyde regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA February 26, 2024
European Commission approves Tecentriq SC, the EU’s first PD-(L)1 cancer immunotherapy subcutaneous injection for multiple cancer types January 23, 2024
European Commission Approves KRAZATI (adagrasib) for Patients with Advanced NSCLC with a KRASG12C Mutation January 17, 2024
FDA Approves KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy as Treatment for Patients With FIGO 2014 Stage III-IVA Cervical Cancer January 17, 2024
European Commission Approves KEYTRUDA + Chemotherapy for New 1L Indications in Advanced HER2-Negative Gastric or GEJ Adenocarcinoma in Tumors Expressing PD-L1 (CPS ≥1) and Advanced Biliary Tract Cancer January 4, 2024
FDA Approves WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI December 19, 2023
FDA Approves Expanded Indication for KEYTRUDA Plus Padcev for 1L Treatment of Adult Patients With Locally Advanced or Metastatic Urothelial Cancer December 19, 2023
Abecma Approved in Earlier Lines of Therapy for Patients with R/R Multiple Myeloma in Japan December 11, 2023
